Elanco Animal Health Incorporated

NYSE:ELAN

Drug Manufacturers - Specialty & Generic

Healthcare
$26.70 -3.47%

-$0.84 today

Market cap
$13.35B
Beta
1.70
P/E (TTM)
-48.1
EPS (TTM)
-$0.49
52W Low $13.16High $27.72

Volume 5.78M

Average 6.04M

ELAN Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Elanco Animal Health IncorporatedNYSE: ELAN

Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026

Net change in cash growth accelerates

Q3 FY2026 net change in cash of $65M (cash outflow) rose 91.2% year over year, ahead of the -366.7% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 1.6% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +91.2% holds above the trailing-twelve-month pace of -366.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$65M-163.7% QoQ
Last fiscal yearDec 2025
$77M-33.6% YoY
LTMSep 2026
-$40M-366.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.2%——
1 year-33.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
77M USD
Year-over-year change
-33.6%
4-year CAGR
-12.6%

Net Change in Cash vs competitors

How ELAN compares with its peers on the latest reported figures

  • ELAN's LTM Sep 2026 net change in cash of $40M is the 3rd largest of the 6 companies compared; the peer median is $10.63M.
  • Its year-over-year change of -366.7% is the lowest of 6, against a peer median of -65.9%.
  • Net change in cash amounts to 0.8% of revenue for ELAN, versus a peer median of 1.0%.
ELAN Competitors Peer median
Net Change in Cash for ELAN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$1.13B -65.9%-33.2%1.7%
ZTSZoetis Inc.LTM Jun 2026$97M -30.2%+50.2%1.0%
ELANElanco Animal Health IncorporatedLTM Sep 2026$40M -366.7%—0.8%
NEOGNeogen CorporationLTM Aug 2026$33.12M +79.9%-21.9%3.7%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$10.63M -89.4%+50.2%0.2%
PAHCPhibro Animal Health CorporationLTM Mar 2026$5.43M -153.6%—0.4%
Peer median (excluding ELAN) $10.63M-65.9%+14.1%1.0%

Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(472M)(78M)(1.23B)338M(232M)
Depreciation & Amortization716M682M694M662M680M
Deferred Income Tax(154M)(57M)(80M)(112M)(134M)
Stock-Based Compensation66M59M46M55M68M
Change in Working Capital(87M)(462M)(300M)149M99M
Accounts Receivables(3M)14M(40M)12M(12M)
Inventory27M(269M)(160M)44M(57M)
Accounts Payables(120M)(98M)(94M)82M147M
Other Working Capital9M(109M)(6M)11M21M
Other Non-Cash Items414M308M1.14B(551M)79M
Operating Cash Flow483M452M271M541M560M
Capital Expenditures(197M)(184M)(154M)(147M)(276M)
Acquisitions (Net)(342M)13M(19M)1.32B0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities9M(8M)(10M)(14M)(3M)
Investing Cash Flow(530M)(179M)(169M)1.16B(279M)
Debt Repayment177M(517M)(77M)(1.48B)(563M)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities33M(32M)(6M)(17M)288M
Financing Cash Flow210M(549M)(83M)(1.49B)(275M)
Effect of Forex Changes(31M)(17M)(12M)(91M)71M
Net Change in Cash132M(293M)7M116M77M
Free Cash Flow286M268M117M394M284M

Elanco Animal Health Incorporated

NYSE:ELAN

Intrinsic Alpha fair value

Locked

Current Price

$26.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.